Supplementary Material

# Supplementary Tables

|  |  |  |
| --- | --- | --- |
| **Supplementary Table 1. Primers used in the study.** | |  |
| Gene | Primer sequences |  |
|  | Forward | Reverse |
| AC156455.1 | CAGCTGTGGCACCAAAAGTC | TGCTTGGCCAGAGTTAGGTG |
| AC011462.4 | ATGACGACCCTGTTGGCATT | CGTGGGTCATGTGAGTGTGA |
| TSPEAR-AS2 | TCATCTTTGGGTGGAGCCAC | TGACCCAGTCTCCTGTCAGT |
| AL137782.1 | CAACTCACGTCAGCCTCAGT | AGAACAACTGCTCCAGAGGC |
| LINC01857 | TTAAGAAGCTCCACTGCGCT | ACATCACGCAGAGGCTTTGA |
| ALMS1-IT1 | CATGCACACAGTTGCTGAGG | TACCCGTCAAGAACCACTGC |
| AC022613.2 | GCACTGCACAGGAAACACAG | GAAGCAGGGAAGTGTGAGCT |
| AC022144.1 | TAATTTGGCGCTCCCCACTT | GATGCCCTTCCAGTTCCCAA |
| GAPDH | ACCACAGTCCATGCCATCAC | TCCACCACCCTGTTGCTGTA |

# Supplementary Figures



**Supplementary Figure 1.** Identification of OS-related clinical variables by Kaplan-Meier analysis. (A) Kaplan-Meier curves stratified by age; (B) Kaplan-Meier curves stratified by gender; (C) Kaplan-Meier curves stratified by tumor stages;



**Supplementary Figure 2.** DCA curves. **(A–C)** DCA curves of 1-, 3-, and 5-year OS predicted by the nomogram, the prognostic signature, and clinical variables in the training cohort.



**Supplementary Figure 3.** DCA curves. **(A–C)** DCA curves of 1-, 3-, and 5-year OS predicted by the nomogram, the prognostic signature, and clinical variables in the TCGA internal validation cohort.



**Supplementary Figure 4.** DCA curves. **(A–C)** DCA curves of 3-, 5-, and 6-year OS predicted by the nomogram, the prognostic signature, and clinical variables in the qRT-PCR external validation cohort.